LSIPR 50 2018: Roy Waldron

14-08-2018

Roy Waldron was selected in the LSIPR 50 2018 publication for​ ​his influence on the life sciences industry. He featured in the legal section, as LSIPR reports.

roywaldron_pfizer.jpg

 

Name: Roy Waldron


Roy Waldron, LSIPR 50, Pfizer, oncology, vaccines, inflammation, immunology, rare diseases, metabolic diseases, biosimilars

LSIPR